| Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
|---|
ID: ALA2381785
Max Phase: Preclinical
Molecular Formula: C25H32N4O2
Molecular Weight: 420.56
Molecule Type: Small molecule
Associated Items:
Representations
Canonical SMILES: CCCCCn1cc(C(=O)NC2CCCCCC2)c(=O)n2nc(-c3ccccc3)cc12
Standard InChI: InChI=1S/C25H32N4O2/c1-2-3-11-16-28-18-21(24(30)26-20-14-9-4-5-10-15-20)25(31)29-23(28)17-22(27-29)19-12-7-6-8-13-19/h6-8,12-13,17-18,20H,2-5,9-11,14-16H2,1H3,(H,26,30)
Standard InChI Key: SLQJDOXEUFHUGL-UHFFFAOYSA-N
Associated Targets(Human)
Cannabinoid CB2 receptor 16942 Activities
Cannabinoid CB1 receptor 20913 Activities
| Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
|---|
Associated Targets(non-human)
Cannabinoid CB2 receptor 721 Activities
| Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
|---|
Cannabinoid CB1 receptor 3458 Activities
| Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
|---|
Molecule Features
| Natural Product: No | Oral: No | Chemical Probe: No | Parenteral: No |
| Molecule Type: Small molecule | Topical: No | First In Class: No | Black Box: No |
| Chirality: No | Availability: No | Prodrug: No |
Drug Indications
| MESH ID | MESH Heading | EFO IDs | EFO Terms | Max Phase for Indication | References |
|---|
Mechanisms of Action
| Mechanism of Action | Action Type | target ID | Target Name | Target Type | Target Organism | Binding Site Name | References |
|---|
Properties
| Molecular Weight: 420.56 | Molecular Weight (Monoisotopic): 420.2525 | AlogP: 4.81 | #Rotatable Bonds: 7 |
| Polar Surface Area: 68.40 | Molecular Species: NEUTRAL | HBA: 5 | HBD: 1 |
| #RO5 Violations: 0 | HBA (Lipinski): 6 | HBD (Lipinski): 1 | #RO5 Violations (Lipinski): 0 |
| CX Acidic pKa: | CX Basic pKa: | CX LogP: 4.99 | CX LogD: 4.99 |
| Aromatic Rings: 3 | Heavy Atoms: 31 | QED Weighted: 0.44 | Np Likeness Score: -1.17 |
References
| 1. Aghazadeh Tabrizi M, Baraldi PG, Saponaro G, Moorman AR, Romagnoli R, Preti D, Baraldi S, Ruggiero E, Tintori C, Tuccinardi T, Vincenzi F, Borea PA, Varani K.. (2013) Discovery of 7-oxopyrazolo[1,5-a]pyrimidine-6-carboxamides as potent and selective CB(2) cannabinoid receptor inverse agonists., 56 (11): [PMID:23697626] [10.1021/jm400182t] |
Source
Source(1):